Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MB | P02144 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27949248 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL28723875 | 0.84 | HDAC3 (0.42) | — | |
| SCHEMBL12678593 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL9000935 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL28849756 | 0.79 | NAMPT (0.48) | CA12CA1CA9 | |
| SCHEMBL5630257 | 0.77 | KCNQ3 (0.55) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL7964257 | 0.76 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL28369609 | 0.75 | KDM4E (0.44) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL1430701 | 0.74 | NPSR1 (0.55) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL6664102 | 0.74 | MEN1 (0.40) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| EP-2448934-B1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES | ASTRAZENECA AB (SE) | 2014-05-21 | — | — | EP | disclosed |
| EP-2448934-B1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES | ASTRAZENECA AB (SE) | 2014-05-21 | — | — | EP | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| CN-102482264-A | 2-carbamoyl-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| EP-2448934-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | AstraZeneca AB (SE) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | C1R, HTR4, HTR2C | SMN1; SMN2 1878/4885HTT 391/4885L3MBTL1 2021/4885 |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | C1R, CBR1, HTR2C | SMN1; SMN2 2251/4885HTT 313/4885L3MBTL1 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.